


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-4.16%
+13.77%
+21.93%
-4.89%
OGN
Organon &
$7.29
Strengths

Earnings are forecast to grow
OGN Price Performance
$8.2 (-11.10%)
$7.27 (+0.28%)
$10.84 (-32.75%)
$15.62 (-53.33%)
Overall standing based on market and analyst consensus.
Hover over the category for more information
Earnings
Earnings
Below analyst estimate
Revenue declined YoY
Rating
Rating
Momentum
Momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
OGN Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
OGN Street Sentiment is unimpressive and have negative views on the near-term outlook
OGN has Low risk level
Sentiments overview associated with events and the stock performance
Average key support and resistance price levels
PFE
Pfizer
27.65
+2.03%
ABT
Abbott Laboratories
116.35
+0.08%
ABBV
AbbVie
232.08
+3.29%
What is OGN current stock price?
What are OGN stock strengths?
What is OGN Risk Level?
What is OGN market cap and volume?
What is OGN current Stock IQ?
Should I buy OGN stock right now?
Is OGN a Strong Buy right now?
What does a 'Strong Buy' rating mean for OGN?
What does a 'Strong Sell' rating mean for OGN?
What factors influence OGN's Stock IQ?
Join our subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
OGN
Organon &
Current Price
$7.29
Runners Also Watch
PFE
Pfizer
27.65
+2.03%
ABT
Abbott Laboratories
116.35
+0.08%
ABBV
AbbVie
232.08
+3.29%

OGN Price Performance
$8.2 (-11.10%)
$7.27 (+0.28%)
$10.84 (-32.75%)
$15.62 (-53.33%)
OGN Analysts Opinion
Overall standing per market and analyst expectations.
Hover over the category for more information
Earnings
Earnings
Below analyst estimate
Revenue declined YoY
Rating
Rating
Momentum
Momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
OGN Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
OGN Street Sentiment is unimpressive and have negative views on the near-term outlook
OGN has Low risk level
Average key support and resistance price levels
OGN Stock IQ
Stock Insights
Strengths

Earnings are forecast to grow
OGN Latest Analysis
Organon & Co. (OGN) Posts FY Adjusted EPS of $3.66 EBITDA Margin at 30.7%. Organon &. Co. (NYSE:OGN) is among the 7 Oversold Pharma Stocks to Buy Now. Organon &. Co. (NYSE:OGN) is among the most oversold pharma stocks. TheFly reported on February 12 that OGN announced its fourth-quarter and full-year 2025 financial results. According to the report for the full year the companys revenue totaled $6.2 billion which [….]
Mon Feb 23, 2026
Whats Driving the Market Sentiment Around Organon & Co?. ) short interest as a percent of float has fallen 7.4% since its last report. According to exchange reported data there are now Short interest is the number of shares that have been sold short but have not yet been covered or closed out. is when a trader sells shares of a company they do not own with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.Short ...
Fri Feb 20, 2026
Organon rises after update on independent review.
Fri Feb 20, 2026
Organon shares jump 6% after audit finds no misconduct.
Fri Feb 20, 2026
Ex-Dividend Reminder: Murphy USA American States Water and Organon . Looking at the universe of stocks we cover at Dividend Channel on 2/23/26 Murphy USA Inc (Symbol: MUSA) American States Water Co (Symbol: AWR) and Organon &. Co (Symbol: OGN) will all trade ex-dividend for their respective upcoming dividends. Murphy USA Inc will pay its q
Thu Feb 19, 2026
Organon & Co. Q4 Earnings Call Highlights. Key Points-2026 guidance roughly flat: Organon guided to about $6.2 billion in revenue and $1.9 billion in adjusted EBITDA for 2026 with adjusted gross margin expected to decline ~75–100 basis points and headwinds including a ~120-basis-point revenue hit from the JADA divestiture plus LOE and
Fri Feb 13, 2026
Organon declares $0.02 dividend.
Thu Feb 12, 2026
FIND US ON
Unlock the knowledge that 5,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained.
The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.